chromosome 17 (human)

chromosome 17 (human) Chromosome 17 is one of the 23 pairs of human chromosomes and carries a dense complement of genes implicated in development, cancer, and neurological function. It spans approximately 83 million base pairs and includes regions with high gene density, segmental duplications, and clinically significant loci such as those for BRCA1, TP53, and NF1. Studies by groups at the Human Genome Project, the Wellcome Trust Sanger Institute, and the National Institutes of Health have characterized its sequence, variation, and structural complexity.

Structure and Genomic Features

Chromosome 17 consists of a short arm (17p) and a long arm (17q) separated by a submetacentric centromere described in karyotypes from the International System for Human Cytogenomic Nomenclature used by clinical laboratories like those at Mayo Clinic and Johns Hopkins Hospital. Cytogenetic bands such as 17p13.1 and 17q21.31 host critical loci studied by consortia including the 1000 Genomes Project, the ENCODE Project Consortium, and the Genome Reference Consortium. Recurrent structural variants such as the 17q21.31 microdeletion and inversion polymorphisms have been mapped using techniques developed at the Broad Institute, utilizing data from the HapMap Project and resequencing efforts by teams at University of Washington and Cold Spring Harbor Laboratory. Segmental duplications on 17p have been characterized in work from the Sanger Centre and in comparative maps produced by the Max Planck Institute.

Gene Content and Notable Genes

Chromosome 17 encodes approximately 1,200 protein-coding genes annotated in databases maintained by the National Center for Biotechnology Information and curated in the Ensembl and UCSC Genome Browser resources used by researchers at institutions such as Harvard Medical School and Stanford University School of Medicine. Prominent tumor suppressor and DNA repair genes include TP53 and BRCA1, while neurofibromatosis type 1 is caused by mutations in NF1 described in clinical reports from Children's Hospital of Philadelphia and case series in journals like The New England Journal of Medicine. Other notable loci include the microtubule-associated gene MAPT linked to neurodegenerative research at the National Institute on Aging, the immune-related gene cluster containing TREM2 investigated by teams at Massachusetts General Hospital, and developmental regulators such as HOXB9 studied at the European Molecular Biology Laboratory. Oncogenes and cancer-associated genes like ERBB2 (HER2) have driven therapeutic development at pharmaceutical companies and academic centers including Dana-Farber Cancer Institute and MD Anderson Cancer Center. Genes for metabolic and endocrine function on 17 include SREBF1 characterized by researchers at Karolinska Institutet.

Function and Expression

Genes on chromosome 17 participate in diverse cellular processes investigated in mechanistic studies at institutions such as Princeton University and Yale University. DNA repair pathways involving TP53 intersect with work on BRCA1-mediated homologous recombination explored by investigators at Cold Spring Harbor Laboratory and Imperial College London. Neurodevelopmental expression patterns of MAPT and NF1 have been profiled in collaborations between the Allen Institute for Brain Science and clinical neurosciences units at UCL Queen Square Institute of Neurology, while oncogenic amplification of ERBB2 informs targeted therapy trials run by groups at Memorial Sloan Kettering Cancer Center and Royal Marsden Hospital. Transcriptomic atlases from the GTEx Project and single-cell studies from the Wellcome Centre for Human Genetics reveal tissue-specific expression of 17q genes across organs studied at centers like Cleveland Clinic and Mount Sinai Health System.

Associated Disorders and Clinical Significance

Pathogenic variants and structural rearrangements on chromosome 17 underlie syndromes and cancers documented in clinical practice at Cincinnati Children's Hospital Medical Center and referenced in guidelines by organizations such as the American College of Medical Genetics and Genomics. Deletions at 17p13.3 cause Miller–Dieker lissencephaly syndrome described in reports from pediatric neurology groups at Boston Children's Hospital, while 17q21.31 microdeletion syndrome has been characterized by European consortia including researchers at University of Cambridge and University College London. Germline mutations in BRCA1 increase breast and ovarian cancer risk managed by hereditary cancer programs at Cancer Research UK and the US Preventive Services Task Force recommendations influence screening at centers like City of Hope. Somatic alterations of TP53 and amplifications of ERBB2 are central to oncology practice guidelines at NCCN and treatment protocols at MD Anderson Cancer Center. Neurofibromatosis type 1 due to NF1 mutations is treated and studied at specialized clinics such as those at Seattle Children's Hospital.

Evolutionary Conservation and Comparative Genomics

Comparative analyses of chromosome 17 regions have been undertaken by evolutionary genomics teams at the Max Planck Institute for Evolutionary Anthropology and the Smithsonian Institution comparing human 17 to syntenic regions in chimpanzee, mouse, and dog genomes sequenced by projects at the Mouse Genome Informatics consortium and the Broad Institute. Conserved gene order for clusters like HOXB and conserved elements near BRCA1 reflect purifying selection reported in phylogenomic studies published by groups at Princeton University and Stanford University. Lineage-specific expansions and segmental duplications on 17 have been inferred from work involving the Comparative Genomics Group at the Wellcome Sanger Institute and paleogenomic studies comparing Neanderthal and Denisovan sequences produced by teams at the Max Planck Institute.

Category:Human chromosomes